Drug Profile
Research programme: decoy oligonucleotides - DOLTHERA
Alternative Names: decoy ODN; ODNLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Avontec
- Developer DOLTHERA
- Class Oligonucleotides
- Mechanism of Action Genetic transcription inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 07 Mar 2011 No development reported - Preclinical for Atherosclerosis in Germany (Parenteral)
- 07 Mar 2011 No development reported - Preclinical for Rheumatoid arthritis in Germany (Parenteral)
- 07 Mar 2011 No development reported - Preclinical for Transplant rejection in Germany (Parenteral)